Medicenna to Present at Upcoming Investor Conferences in September

September 9, 2020

TORONTO, **Ontario** and **HOUSTON**, **Texas**, September 9, 2020 - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immunooncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference 2020, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Both conferences are being held in September 2020. See below for more details.

Conferences Details:

Event: H.C. Wainwright 22nd Annual Global Investment Conference 2020 (virtual)
Format: Presentation
Date: Wednesday, September 16TH
Time: 10:30 a.m. ET
Webcast: Link

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (virtual)
Format: Fireside Chat
Date: Tuesday, September 22nd
Time: 1:40 p.m. ET
Webcast: Link

Live webcasts of both events will be available in the investor relations section of Medicenna's website at https://ir.medicenna.com/events-and-presentations. After the live webcasts, each event will remain archived on Medicenna's website for approximately 90 days.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is potentially a best-in-class next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulating cancer killing effector T cells and NK cells when compared to competing IL-2 programs. It is anticipated that MDNA11 will be ready for the clinic in 2021. Medicenna's lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. An End of Phase 2 meeting with the FDA is planned for 29th September 2020. MDNA55 has been studied in five clinical trials involving 132 patients, including 112 adults with rGBM.MDNA55 has demonstrated compelling efficacy and has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively. For more information, please visit www.medicenna.com.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements related to the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all patients and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.

Further Information

For further information about the Company please contact:

Elizabeth Williams,
Chief Financial Officer,
416-648-5555,
ewilliams@medicenna.com

Investor Contact

For more investor information, please contact:

Dan Ferry,
Managing Director,
LifeSci Advisors,
617-430-7576,
daniel@lifesciadvisors.com